Filana Therapeutics Inc (FLNA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.81+1.47%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Net cash used in operations stays below $17 million in H1 2026: FCF guidance $14M-$17M vs $17M target.
Filana aims to limit cash use to $17 million in H1 2026. It plans to handle a $31.25 million loss from securities litigation. The company beat earnings estimates in recent quarters. These show some progress despite losses.
Filana is still losing money and faces a big legal cost. Cash use remains high with limited progress. The stock fell 45% from its high, showing weak confidence.
The market prices in a large decline in growth and ongoing losses. Our fair value is about $9.08, reflecting this weak outlook. We see risk if cash use or litigation costs rise.
Breaks if: Net cash used in operations exceeds $17 million in H1 2026
Focus on managing net cash use in operations with a target range for the first half of 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround play in the healthcare sector. The current thesis is cautious, given the company's loss-making status and high risk, despite some recent positive earnings surprises.
The market appears to price in a low level of fragility, reflecting a turbulent sector backdrop rather than a fully expensive situation. FLNA is considered cheap compared to its peers, but the overall confidence in its valuation is low.
Management is focused on cash management and advancing its epilepsy program, but recent financial performance has shown mixed results. The company has experienced a notable drop in momentum, which could impact future performance.
Key factors include the potential for management to cut guidance, which would negatively affect sentiment. Additionally, the performance of sector leaders and the overall jobs report will be crucial in shaping FLNA's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens below -$0.25 next quarter
Breaks if: Loss contingency rises above $31.25 million or unresolved by mid-2026
Plan to address the estimated loss contingency related to securities litigation.
The outlook for FLNA over the next 1 to 3 years is uncertain, with a focus on cash management and sector performance. Not investment advice.